Across TCGA pan-cancer cohorts, PLSCR3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLSCR3 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PLSCR3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLSCR3 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, HNSC, and UCEC are the cancer types where PLSCR3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.539	0.891	<.001	70	view →
HNSC	DFS	Median	II,III,IV	0.992	0.905	.013	10	view →
UCEC	OS	Tertile	III,IV	0.414	1.000	.026	4	view →
GBM	DFS	Quartile	All	0.620	0.857	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PLSCR3 tumor-vs-normal RNA expression · all PLSCR3 data types